CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022

Rhea-AI Summary

CymaBay Therapeutics (NASDAQ: CBAY) announced a conference call on March 17, 2022, at 4:30 PM ET to discuss its financial results for Q4 and the full year ending December 31, 2021. The company, focused on therapies for liver diseases, has achieved breakthrough therapy designation for its first-in-class drug, seladelpar, aimed at treating primary biliary cholangitis (PBC). The audio of the call will be accessible through their investor relations website.

Positive

• Achieved breakthrough therapy designation for seladelpar from the FDA.
• Received PRIority MEdicines status from the European Medicines Agency.
• Obtained orphan drug status for seladelpar in the U.S. and Europe.

Negative

• None.

NEWARK, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 17, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2021 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13726915. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Public Relations Contact:            

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com 

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com 

FAQ

What is the date of CymaBay's upcoming conference call?

CymaBay's conference call is scheduled for March 17, 2022, at 4:30 PM ET.

What financial results will CymaBay discuss on the conference call?

CymaBay will discuss its financial results for the fourth quarter and year ended December 31, 2021.

What is seladelpar, and why is it significant for CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis (PBC) and has received multiple designations highlighting its potential.